Clinical and Preclinical Experience with Gefitinib and Sunitinib

Peter A. Fasching  Michael P. Lux  Claudia Rauh  Sebastian Jud  Matthias W. Beckmann
Frauenklinik, Universitätsklinikum Erlangen, Germany

Key Words
Sunitinib · Gefitinib · Breast cancer · Tyrosine kinase · EGFR · VEGFR

Summary
Gefitinib and sunitinib are new targeted agents in cancer therapy. As a single-target agent gefitinib was one of the first tyrosine kinase inhibitors in solid cancers. It is an inhibitor of the intracellular domain of the epidermal growth factor receptor (EGFR). Most experience with this drug was made in the treatment of non-small cell lung cancer. Its efficacy in most other solid cancers is limited. Several studies could show an association between the response of non-small cell lung cancers to gefitinib and a mutation of the EGFR gene. This mutation changes the target and alters the sensitivity for the drug. In breast cancer limited data of phase II studies showed response rates lower than 2%. Sunitinib as a multitarget agent inhibits several targets like vascular epidermal growth factor receptors (VEGFR) and other receptor tyrosine kinases. The efficacy of sunitinib against tumors is attributable to a direct antitumor activity and to an inhibition of neoangiogenesis. Most data exist for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Sunitinib could clearly improve the systemic treatment of these diseases. In the treatment of metastatic breast cancer response rates for the single agent therapy of 11% could be reported, which made this agent interesting for further phase III studies. These phase III studies are currently ongoing.

Schlüsselwörter
Sunitinib · Gefitinib · Mammakarzinom · Tyrosinkinase · EGFR · VEGFR

Zusammenfassung
**Introduction**

Gefitinib (Iressa®, AstraZeneca, Wedel, Germany) and sunitinib (Sutent®, Pfizer Pharma GmbH, Karlsruhe, Germany) are two examples of receptor tyrosine kinase inhibitors (TKI) which differ in the development status and the number and kind of targeted receptor tyrosine kinases (RTK). This review focuses on the preclinical data, the clinical data and biological markers predicting the response or sensitivity.

**Gefitinib**

Gefitinib (fig. 1) is an orally active TKI, which blocks the epidermal growth factor receptor (EGFR) selectively. It has been tested in several solid cancer types, of which the results for non-small cell lung cancer (NSCLC) were most promising. Erlotinib (Tarceva®, Roche Pharma AG, Grenzach-Whylen, Germany) is another drug, which is inhibiting the EGFR selectively and reversibly, but about that we will not report in this review. As an anilinoquinazoline agent, gefitinib has a highly specific affinity for EGFR. It prevents the dimerisation of the receptor with other human EGF receptors and the autophosphorylation of the intracellular tyrosin kinase domain. This blocks the activation of downstream signalling, which includes the Ras/Raf/mitogen-activated protein kinase (MAPK) pathway, the phosphatidylinositol 3-kinase (PI3K/Akt) pathway and the signal transduction and activation of transcription (STAT) pathway. By blocking EGFR, gefitinib has an influence on cell growth, proliferation, signal transduction, activation of transcription and cell survival and apoptosis.

**Preclinical Data / Phase I Studies**

In preclinical models the cytostatic activity as a single agent or in combination with chemotherapeutic agents has been shown for several cancer cell line types and tumor xenografts like breast cancer, NSCLC, ovarian cancer, colon cancer, and prostate cancer [1, 2]. Phase I studies were conducted with various cancer types, including breast, ovarian, colorectal, head and neck cancer and mostly NSCLC [3–7]. Dose limiting toxicity was reached at doses from 700 mg/day to 1,000 mg/day. Side effects consisted mainly of diarrhea and skin rash. For further studies either a dose of 250 mg/day or a dose of 500 mg/day was chosen.

Treatment with gefitinib is predominantly associated with mild to moderate toxicities confined to the skin and gastrointestinal system. Skin toxicity consists mainly of pustular rash on an erythematous base. Gastrointestinal toxicity consists of loose or watery, intermittent, non-bloody, non-mucoid stools, occasionally with nausea or isolated episodes of emesis. There is no known hematopoietic, cardiovascular or renal toxicity. A total of 12 out of 282 patients with breast cancer were included in 5 phase I trials with gefitinib. The response rate for the total of these pretreated patients with advanced disease was 10% [8]. Data about the efficacy for breast cancer had to be obtained from further phase II studies.

**Phase II Studies**

**Single agent therapy:** A German study by von Minckwitz et al. [9], in which gefitinib was investigated in patients with metastatic breast cancer, who had a previous treatment with anthracyclines and taxanes, showed a response rate in 1,7% (n = 58) of the patients with a dose of 500 mg/day. The median time to progression (TTP) was 2.03 months. Most frequently reported toxicities in this cohort were diarrhea (70.7%), dry skin (27.6%), rash (24.1%), nausea (17.2%), exanthema (13.8%) and fatigue (13.8%) [9].

Another phase II study with 31 women treated metastatic breast cancer patients with a dose of 500 mg/day [10]. No patient had a partial or complete response and 12 patients 38.7% had a stable disease. TTP was reported with 1.77 months. The largest phase II studies were performed with patients with NSCLC and colorectal cancer. The response rate in colorectal cancer patients was <1% [11] and 9–19% in the NSCLC studies [12, 13].

**Combination therapy:** 33 metastatic breast cancer patients have been included into a phase II study with a combination treatment of gefitinib and trastuzumab [14]. Most of these patients (n = 26) were chemotherapy naïve. 1 patient had a complete response and 6 achieved stable disease. TTP was 2.7 months.

Another trial investigated the combination of docetaxel (75 mg/m²) and gefitinib (250 mg per day) in 41 metastatic breast cancer patients as first-line treatment. 12% had a complete response and 42% a partial response.

In the neoadjuvant setting a combination of anastrozol and gefitinib was compared to gefitinib alone in a study with a prospective, randomized and double blind design [15]. These trials offer the opportunity not only to assess the response rate in treatment naïve patients but also to investigate the tumor sample regarding changes of biomarkers and to gain evidence about probable predictive markers for treatment success or to learn about the molecular treatment mechanisms. In this study 56 women were randomized. The primary objective was the inhibition of tumor cell proliferation, as measured by Ki67. One of further secondary objectives was the change of tumor size. The combination arm showed a significantly greater reduction of proliferation. The Ki67 labeling index was reduced by 92.4% in the gefitinib single treatment arm and by 98.0% in the combination arm with anastrozole. Tumor size reduc-
tion of ≥30% was achieved in 14 out of 28 patients with the combination treatment and in 12 of 22 patients receiving gefitinib alone.

**Phase III Data**

Due to the limited effect in phase II trials, no phase III trial with gefitinib was conducted. In advanced NSCLC 2 large controlled and prospectively randomized trials that added gefitinib to the standard chemotherapy could not prove an advantage in overall survival, which was the primary objective of these trials [16, 17].

**Association of Biomarkers with Response**

In NSCLC patients (over)expression of EGFR and the gene mutation status of EGFR are discussed to be associated with the response to a treatment with gefitinib. Concerning the expression of EGFR some studies could not find an association of EGFR expression by immunohistochemistry with the response to gefitinib [18, 19]. Other studies, however, could associate a higher expression of EGFR with a longer survival and better response in patients who are treated with gefitinib [20] and erlotinib [21]. EGFR receptor expression may be a prognostic and a predictive factor. Evaluation of those mixed biomarkers may be difficult in a retrospective data set and bias the results [22]. Further studies are necessary to assess the prognostic and predictive value. Not much is known about biomarker associations in breast cancer patients. The one reported patient in the study of von Minckwitz et al. [9] had no (over)expression of EGFR.

On the genomic level an interesting observation has been made, which showed a major association of mutations in a part of the EGFR gene that could result in an altered ATP binding cleft of the intracellular tyrosine kinase domain. In May 2004 two working groups published associations between the response to gefitinib in lung cancer and the mutation status [23, 24]. A mutation seems to enhance the effect of the tyrosine kinase inhibitor. The initial reports that almost all responders had such a mutation were adjusted by several studies [16, 17].

**Conclusion**

Gefitinib was one of the first oral tyrosine kinase inhibitors used in the treatment of solid cancers. Treatment of NSCLC results in remarkable responses. However, the null results obtained from the large phase III studies and a low anticancer activity of gefitinib in other cancer types reflect on the changing paradigm in drug development. The proof of efficacy of targeted therapies is dependent on functional mechanisms that may be different from patient to patient. Trial designs without having good predictors of response endanger the scientists to conduct large trials in patient populations which a priori may be not suitable for those therapies.

**Sunitinib**

There is some evidence that the inhibition of EGFR results in a down regulation of the VEGFR signaling pathway and VEGFR blockade as well inhibits the autocrine signaling of EGFR [26–28]. Because of this interaction a synergistic effect of EGFR antagonists with anti-angiogenic agents like bevacizumab, which is a recombinant, humanized monoclonal anti-VEGF antibody, was assumed. In a study combining erlotinib with bevacizumab in NSCLC a response rate of 20% and a median survival of 12.6 months [29] was observed. Another agent which blocks VEGFR and other RTK signaling is sunitinib (fig. 2).

Its antitumor activity was shown in several cancer types. It is approved for the treatment of advanced renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors (GIST). In phase I, II and III studies more than 4,000 patients received the drug up to now. Sorafenib is a further multitarget TKI, which has been approved in the United States. These multitarget TKI are recently in the focus of interest, because they inhibit several related pathways and may achieve a better efficacy in a broader spectrum of tumors than single target TKI.

By inhibiting several targets, the efficacy of sunitinib against tumors is attributable to a direct antitumor activity and to an inhibition of neoangiogenesis. As well in solid cancers as in hematological malignancies additional receptor tyrosine kinases (RTK) other than the ones from the HER family are implicated in tumor growth and survival of cancer cells. These RTK include vascular endothelial growth factor receptor 1, 2 and 3 (VEGFR), platelet derived growth factor receptors α and β (PDGFR), the stem cell factor receptor (SCFR or KIT) and FMS-related tyrosine kinase 3-ligand receptor (FLT3R) [30–32].

**Preclinical Data and Phase I Studies**

Dose finding studies have been performed as single and multiple dose studies with a range from 25 mg/d to 100 mg/d. Most of the studies started with a dose of 50 mg/d for 4 weeks followed by an interruption of medication for 2 weeks. The most common toxicities included gastrointestinal effects like diarr-
rhea, nausea, stomatitis and dyspepsia, myelosuppresion including neutropenia and thrombocytopenia, dermatological disorders like dermatitis, alterations of skin, especially hand-foot-syndrome, skin and hair depigmentation. Furthermore fatigue and asthenia have been observed.

**Phase II Data**

The cancer types which were mostly investigated with sunitinib are renal cell carcinoma (RCC), GIST and acute myelogenous leukemia (AML).

**Renal cell carcinoma:** In RCC chemotherapy response rates to common therapies rarely exceed 6% and response rates to interleukin and interferon are about 10–15% [33–36]. 2 phase II studies revealed promising response rates of 40% and 39% for the single agent therapy with sunitinib [37, 38].

**Gastrointestinal stromal tumors:** GIST are the most common sarcoma of the gastrointestinal tract and account for 0.2% of all gastrointestinal malignancies [39]. The median survival for patients who cannot be treated sufficiently by surgery or are metastatic is only 10–23 months [40] and the response rate to chemotherapy for these tumors is poor [40]. With partial responses of about 54% and stable diseases in about 28% of the patients the treatment with imatinib improved the treatment options clearly [41] and it was approved for the treatment of metastatic and non-resectable GIST in February 2001. The treatment effect is assumed to be associated with mutations of the KIT proto-oncogene which can be found in the majority of GIST [42] as well as activating mutations of the PDGFR-α [43].

For the treatment of imatinib-resistant GIST a phase I/II trial showed encouraging clinical activity [44]. The clinical benefit of sunitinib in this trial could be associated with secondary KIT mutations in exon 13 or 14, which was 65% in this subgroup of patients.

**Breast cancer:** In a single arm, open labeled phase II study 64 patients have been treated with 50 mg sunitinib per day for 4 weeks followed by an interruption of treatment for 2 weeks. The patients have been previously treated with anthracyclines and taxanes. 7 patients (11%) had an objective response and 3 patients (5%) had a stable disease which lasted longer than 6 months [45]. In this patient group neutropenia was more common than in previous studies. However, the neutrophil rebound was rapid after treatment rest and there were no cases of neutropenic fever. Other adverse events were as frequent as expected. In order to identify biomarkers which correlate with response, plasma levels of soluble proteins have been analyzed in this trial. Besides changes of VEGF and soluble VEGFR2 and VEGFR3 changes of soluble KIT have been observed. Decreases of soluble KIT >50% by the end of cycle 2 were correlated with significantly better treatment outcomes for time-to-progression and survival [46].

Another multinational phase II study which is recruiting in Germany as well, is a randomized trial comparing sunitinib in anthracylin and taxan resistant patients versus a standard of care single chemotherapy regimen. This trial is addressing the subgroup of triple negative (HER2, estrogen and progesterone receptor negative) breast cancer patients (http://clinicaltrials.gov/show/NCT00246571).

**Phase III Data**

For metastatic RCC a prospectively randomized trial compared a treatment with sunitinib versus a medication with interferon-alpha (IFN-α). It demonstrated a significant improvement in progression free survival and a superior objective response rate for sunitinib over IFN-α [47]. The median progression free survival was almost doubled (24.9 weeks for IFN and 47.3 weeks for sunitinib) and the objective response rate in the sunitinib arm was 24.8% compared to 4.9% in the interferon arm. In breast cancer several phase III trials have been conducted recently.

In imatinib-resistant GIST patients a prospectively randomized, double blinded phase III trial compared a treatment with sunitinib versus a placebo treatment. 207 patients received sunitinib and 105 patients were randomized into the placebo arm [48]. This trial had to be unblinded early because an interim analysis revealed a clear advantage in favor of sunitinib. Patients in the sunitinib arm had a time to progression of 27.3 months and patients in the placebo arm 6.4 months (p < 0.0001). The interim analysis of this phase III trial was part of the FDA approval of sunitinib in January 2006. The data in breast cancer are limited. One study is comparing the treatment of metastatic breast cancer with docetaxel versus a combination of docetaxel and sunitinib (http://clinicaltrials.gov/show/NCT00393939). Another clinical investigation compares sunitinib plus paclitaxel versus bevacizumab plus paclitaxel in patients with advanced breast cancer (http://clinicaltrials.gov/ct/show/NCT00373256). Capacetabine as a single agent treatment for patients with metastatic breast cancer after an anthracycline and taxane treatment is compared to sunitinib as a single agent treatment in a phase III study, which is about to enroll more than 700 patients (http://clinicaltrials.gov/show/NCT00373113). Further phase III studies comparing combinations of sunitinib with cytostatic agents versus chemotherapy alone are planed.

**Conclusion**

Sunitinib is a well tolerated multitarget TKI with a favorable toxicity profile. It is established in the treatment of metastatic renal cell carcinoma and the treatment of gastrointestinal stromal tumors. For further malignancies like breast cancer promising data of phase II studies have been published. Results of large phase III trials are still pending as these trials have recently been conducted.
References


Gefitinib and Sunitinib: Clinical and Preclinical Experience with


Clinical and Preclinical Experience with Gefitinib and Sunitinib

Breast Care 2007;2:68–73